La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Cencora Crescita futura

Future criteri di controllo 2/6

Cencora prevede che gli utili e i ricavi cresceranno rispettivamente di 11.3% e 6.9% all'anno. Si prevede che l'EPS crescerà di 14% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 98.7% in 3 anni.

Informazioni chiave

11.3%

Tasso di crescita degli utili

14.0%

Tasso di crescita dell'EPS

Healthcare crescita degli utili	19.3%
Tasso di crescita dei ricavi	6.9%
Rendimento futuro del capitale proprio	98.6%
Copertura analitica	Good
Ultimo aggiornamento	21 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Market Participants Recognise Cencora, Inc.'s (NYSE:COR) Earnings

Jul 16

Cencora: Potential Exists, But Ambiguous Valuations And Data Breach Risks Are Concerning

Jun 30

Cencora, Inc.'s (NYSE:COR) Intrinsic Value Is Potentially 53% Above Its Share Price

Mar 18

Cencora (NYSE:COR) Seems To Use Debt Quite Sensibly

Feb 25

Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Feb 07

Cencora, Inc.'s (NYSE:COR) Business Is Yet to Catch Up With Its Share Price

Jan 05

Cencora: Continued Economic Value On The Table Across All Investment Horizons

Jan 04

A Look At The Fair Value Of Cencora, Inc. (NYSE:COR)

Dec 15

Cencora (NYSE:COR) Is Paying Out A Larger Dividend Than Last Year

Nov 05

Is Cencora (NYSE:COR) A Risky Investment?

Nov 03

Cencora: New Name, Same Old Economic Leverage, Reiterate Buy

Oct 18

AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 34% Below Their Intrinsic Value Estimate

Aug 01

AmerisourceBergen: Great Company, Wrong Price (Rating Downgrade)

Jul 28

We Think AmerisourceBergen (NYSE:ABC) Can Stay On Top Of Its Debt

Jun 19

Is AmerisourceBergen Corporation (NYSE:ABC) Trading At A 28% Discount?

May 01

Here's Why We Think AmerisourceBergen (NYSE:ABC) Is Well Worth Watching

Apr 10

AmerisourceBergen (NYSE:ABC) Has A Pretty Healthy Balance Sheet

Mar 02

AmerisourceBergen declares $0.485 dividend

Feb 01

AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 25% Below Their Intrinsic Value Estimate

Jan 28

AmerisourceBergen partners with pharmaceutical company Civica

Jan 23

AmerisourceBergen: What Does The Valuation Look Like After The Recent Price Rise?

Jan 13

Does AmerisourceBergen (NYSE:ABC) Deserve A Spot On Your Watchlist?

Jan 10

AmerisourceBergen sued by DoJ over suspicious opioid orders

Dec 29

Previsioni di crescita degli utili e dei ricavi

NYSE:COR - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
9/30/2026	334,144	2,530	3,345	3,898	14
9/30/2025	313,474	2,274	2,883	3,443	15
9/30/2024	292,609	2,030	2,626	3,059	14
6/30/2024	283,831	1,856	3,831	4,311	N/A
3/31/2024	276,537	1,852	2,112	2,578	N/A
12/31/2023	271,579	1,867	3,630	4,086	N/A
9/30/2023	262,173	1,745	3,453	3,911	N/A
6/30/2023	254,425	1,689	2,793	3,249	N/A
3/31/2023	247,543	1,617	2,447	2,913	N/A
12/31/2022	241,805	1,729	2,057	2,550	N/A
9/30/2022	238,587	1,699	2,207	2,703	N/A
6/30/2022	236,325	1,842	2,061	2,548	N/A
3/31/2022	229,666	1,727	2,851	3,347	N/A
12/31/2021	221,101	1,614	2,174	2,627	N/A
9/30/2021	213,989	1,540	2,228	2,667	N/A
6/30/2021	204,321	-3,744	2,564	2,956	N/A
3/31/2021	196,282	-3,747	1,284	1,660	N/A
12/31/2020	194,546	-3,222	2,600	2,967	N/A
9/30/2020	189,894	-3,409	1,837	2,207	N/A
6/30/2020	186,287	1,570	1,250	1,581	N/A
3/31/2020	186,159	1,582	1,943	2,236	N/A
12/31/2019	182,061	649	1,710	2,008	N/A
9/30/2019	179,589	855	2,034	2,344	N/A
6/30/2019	177,248	956	2,018	2,337	N/A
3/31/2019	175,151	930	2,263	2,592	N/A
12/31/2018	172,866	1,190	1,538	1,880	N/A
9/30/2018	167,940	1,658	1,075	1,411	N/A
6/30/2018	163,763	1,081	1,783	2,126	N/A
3/31/2018	159,327	855	N/A	1,059	N/A
12/31/2017	155,441	979	N/A	1,945	N/A
9/30/2017	153,144	364	N/A	1,504	N/A
6/30/2017	151,584	855	N/A	1,478	N/A
3/31/2017	149,759	1,154	N/A	1,915	N/A
12/31/2016	148,310	1,346	N/A	1,997	N/A
9/30/2016	146,850	1,428	N/A	3,178	N/A
6/30/2016	144,759	1,643	N/A	2,986	N/A
3/31/2016	142,111	1,508	N/A	3,916	N/A
12/31/2015	139,082	391	N/A	3,777	N/A
9/30/2015	135,962	-138	N/A	3,922	N/A
6/30/2015	132,080	-431	N/A	3,591	N/A
3/31/2015	128,195	-658	N/A	2,989	N/A
12/31/2014	123,981	35	N/A	3,364	N/A
9/30/2014	119,569	282	N/A	1,465	N/A
6/30/2014	112,449	267	N/A	602	N/A
3/31/2014	104,008	344	N/A	157	N/A
12/31/2013	96,076	368	N/A	26	N/A
9/30/2013	87,959	493	N/A	788	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di COR ( 11.3% all'anno) è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Si prevede che gli utili di COR ( 11.3% all'anno) cresceranno più lentamente rispetto al mercato US ( 15.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di COR cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di COR ( 6.9% all'anno) crescerà più lentamente rispetto al mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di COR ( 6.9% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di COR sarà molto alto tra 3 anni ( 98.7 %).

Cencora Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Cencora, Inc. Reaffirms Guidance for Year 2024

Price target increased by 9.0% to US$235

Consensus EPS estimates fall by 14%

Recent updates

Chairman notifies of intention to sell stock

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Third quarter dividend of US$0.51 announced

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cencora, Inc. Declares Quarterly Cash Dividend, Payable on August 26, 2024

Chairman notifies of intention to sell stock

Market Participants Recognise Cencora, Inc.'s (NYSE:COR) Earnings

Cencora, Inc. to Report Q3, 2024 Results on Jul 31, 2024

Cencora: Potential Exists, But Ambiguous Valuations And Data Breach Risks Are Concerning

Are Investors Undervaluing Cencora, Inc. (NYSE:COR) By 43%?

Chairman notifies of intention to sell stock

Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly

Insider exercised options and sold US$3.5m worth of stock

Chairman exercised options and sold US$1.4m worth of stock

Do Cencora's (NYSE:COR) Earnings Warrant Your Attention?

Second quarter dividend of US$0.51 announced

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on May 24, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cencora, Inc. (NYSE:COR) announces an Equity Buyback for $2,000 million worth of its shares.

Executive VP & COO exercised options and sold US$4.9m worth of stock

Cencora, Inc. to Report Q2, 2024 Results on May 01, 2024

Investors Interested In Cencora, Inc.'s (NYSE:COR) Earnings

Cencora Remains Chronically Undervalued, With Material Growth Potential

Chairman exercised options and sold US$1.6m worth of stock

Cencora, Inc.'s (NYSE:COR) Intrinsic Value Is Potentially 53% Above Its Share Price

Cencora, Inc. Reaffirms Guidance for Year 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora (NYSE:COR) Seems To Use Debt Quite Sensibly

Cencora’s FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products

Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There

First quarter dividend of US$0.51 announced

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.0% to US$235

Consensus EPS estimates fall by 14%

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on February 26, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc. to Report Q1, 2024 Results on Jan 31, 2024

Cencora, Inc.'s (NYSE:COR) Business Is Yet to Catch Up With Its Share Price

Cencora: Continued Economic Value On The Table Across All Investment Horizons

Chairman recently sold US$8.7m worth of stock

A Look At The Fair Value Of Cencora, Inc. (NYSE:COR)

Chairman exercised options and sold US$3.1m worth of stock

Insider recently sold US$2.0m worth of stock

Executive VP & CFO exercised options and sold US$3.1m worth of stock

Cencora (NYSE:COR) Is Paying Out A Larger Dividend Than Last Year

Cencora, Inc. Declares Quarterly Dividend, Payable November 27, 2023

Is Cencora (NYSE:COR) A Risky Investment?

Full year 2023 earnings: EPS misses analyst expectations

Cencora: New Name, Same Old Economic Leverage, Reiterate Buy

Chairman exercised options and sold US$2.7m worth of stock

Cencora, Inc. to Report Q4, 2023 Results on Nov 02, 2023

Insider exercised options and sold US$2.0m worth of stock

Now 20% undervalued after recent price drop

Chairman exercised options and sold US$1.0m worth of stock

Now 21% undervalued

Amerisourcebergen Corporation Elects Werner Baumann and Lauren Tyler to Its Board of Directors

Chairman notifies of intention to sell stock

AmerisourceBergen Corporation Declares Quarterly Cash Dividend, Payable on August 28, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 34% Below Their Intrinsic Value Estimate

AmerisourceBergen: Great Company, Wrong Price (Rating Downgrade)

Chairman notifies of intention to sell stock

AmerisourceBergen Corporation to Report Q3, 2023 Results on Aug 02, 2023

Insider exercised options and sold US$3.0m worth of stock

We Think AmerisourceBergen (NYSE:ABC) Can Stay On Top Of Its Debt

Chairman exercised options and sold US$1.1m worth of stock

TPG Inc. (NasdaqGS:TPG), AmerisourceBergen Corporation (NYSE:ABC) and the management team of OneOncology, Inc. acquired OneOncology, LLC from General Atlantic Service Company, L.P. and others.

Executive VP & Chief Legal Officer recently sold US$731k worth of stock

Chairman exercised options and sold US$966k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Is AmerisourceBergen Corporation (NYSE:ABC) Trading At A 28% Discount?